New Cancer Drug Opens Floodgates of Hope Beyond Pancreatic Cancer
A new drug, daraxonrasib, shows promise in extending survival for patients with advanced pancreatic cancer. In a phase 3 trial, it doubled the average survival time compared to traditional chemotherapy. The drug targets a specific mutation in the KRAS gene, which is prevalent in pancreatic cancer and may also have applications for other types of cancer.
- ▪Daraxonrasib has been shown to double the survival time of patients with advanced pancreatic cancer.
- ▪The drug targets a mutation in the KRAS gene, which is found in over 90% of pancreatic cancers.
- ▪Results from the trial were presented at the American Society of Clinical Oncology’s annual meeting and published in the New England Journal of Medicine.
Opening excerpt (first ~120 words) tap to expand
New Cancer Drug Opens Floodgates of Hope Beyond Pancreatic Cancer By Ward Clark | 3:06 PM on May 31, 2026 The opinions expressed by contributors are their own and do not necessarily represent the views of RedState.com. AP Photo/Jose Luis Magana, File A few years back, we learned that a dear friend of ours had been diagnosed with pancreatic cancer. She was a vibrant woman in her mid-40s, with a husband who loved her beyond words, and a young daughter just spreading her wings to enter her adult life. When our friend was diagnosed, they told her to plan on no more than three months. Advertisement googletag.cmd.push(function () { googletag.display("div-gpt-300x250_2"); //googletag.pubads().refresh([gptAdSlot["div-gpt-300x250_2"]]) }); She lasted five.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at RedState.
Discussion
0 commentsMore from RedState
